First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

(2014) Francesco Panza et al.   Expert Review of Clinical Immunology

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease

(2013) Kaj Blennow et al.   NEUROPSYCHOPHARMACOLOGY

Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future

(2013) Niels D Prins et al.   Alzheimers Research & Therapy

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab

(2011) Christopher Carlson et al.   Alzheimers & Dementia

Three cases of apparent Vasogenic Edema (VE) from a phase 2 clinical trial of the gamma secretase Inhibitor BMS-708163 in patients with mild-to-moderate AD

(2011) Reisa Sperling et al.   Alzheimers & Dementia

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

(2010) Ronald S. Black et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY